No Data
On November 21, cspc pharma (01093) spent 29.6878 million HKD to repurchase 5.68 million shares.
cspc pharma (01093) announced that on November 21, 2024, the company invested 2,968.78...
The opening ceremony of the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute.
The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute", established by the special zone government and fully owned, officially opened today (21st) at the Hong Kong Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Center" in Shenzhen Park also opened on the same day. The "one institute and one center" has become the first benchmark for the coordinated development of the "one zone and two parks" in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Secretary for Administration and Home Affairs, Cheuk Wing-hing, stated that the National "14th Five-Year Plan" clearly supports Hong Kong in building an international innovation and technology center. The "Development Plan for Shenzhen Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone" also strongly supports the coordinated development of science and te
November 20th buyback collection | tencent, aia insurance and others have successively repurchased, with tencent spending 0.701 billion Hong Kong dollars.
According to documents disclosed by hkex on November 21, tencent (00700.HK), aia (01299.HK), among others, repurchased shares. ① Tencent (00700.HK) repurchased 1.71 million ordinary shares on November 20, involving 0.701 billion Hong Kong dollars, with a repurchase price ranging from 413.4 Hong Kong dollars to 406.6 Hong Kong dollars per share. Since the repurchase authorization resolution, the cumulative number of repurchased securities is 0.185 billion shares, accounting for 1.961% of the number of issued shares at the time of the ordinary resolution passing. ② AIA (01299.HK)
Express News | Yesterday, a total of 44 Hong Kong stocks were repurchased by companies, with tencent having the largest repurchase amount.
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Bocom Intl lowers the target price of CStone Pharmaceuticals (01093.HK) to 5.8 yuan. Various business sectors in the third quarter are under severe pressure.
Bocom Intl published a research report stating that cspc pharma (01093.HK) faced severe pressure in various business sectors in the third quarter, with revenue and net profit dropping by 17.8% and 50.4% respectively. During this period, the prescription drug business saw a revenue decline of 20%; revenue from active pharmaceutical ingredients and functional foods also decreased. Management expects that the group will launch six new products from the end of this year to next year, which will drive a return to positive growth in operating income outside of BD next year, while R&D expenses are expected to see double-digit growth as the innovative pipeline advances at full speed. Bocom Intl mentioned that cspc's BD is about to enter a harvest period, and the group anticipates generating at least two external licensing transactions each year in the future, and
No Data
No Data